Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents

Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents

Objectives: Targeting tumor necrosis factor (TNF) with biologic agents, such as infliximab and adalimumab, is a widely used and effective therapeutic strategy in inflammatory bowel disease (IBD). Unfortunately, a significant number of patients fail to respond or lose response over time to these agen...

Full description

Bibliographic Details
Main Authors: Vu Q. Nguyen, Kristin Eden, Holly A. Morrison, Megan B. Sammons, Kristin K. Knight, Siena Sorrentino, Rebecca M. Brock, Douglas J. Grider, Irving C. Allen, Dario Sorrentino
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Pharmacology
Subjects:
noncanonical NF-κB pathway
anti-TNF agents
inflammatory bowel disease
Crohn’s disease
ulcerative colitis
alternative pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.655887/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.655887/full

Similar Items